This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Danny Crawford, PhD
Director, Nucleic Acid Process Sciences at Intellia Therapeutics


Danny is Director of Nucleic Acid Process Sciences in the Intellia Tech Ops organization, where he leads pre-clinical and early-phase mRNA and LNP Process Development activities. During his 7 years at Intellia, he has helped drive Intellia’s mRNA process and analytical strategies. Collectively, in both industry and academic roles, he’s focused on RNA biochemistry for the past 20 years.

Agenda Sessions

  • Chairman’s Remarks: Novel RNA-based Therapeutic and Vaccine Platforms

  • Editing the Genome with Cas9 mRNA